Talvey + Tecvayli dual bispecific regimen demonstrates high efficacy in R/R

At EHA 2025, updated data from the Phase II RedirecTT-1 study evaluated the combination of talquetamab (Talvey) and teclistamab (Tecvayli) in patients with relapsed/refractory multiple myeloma (R/R MM) who had triple-class refractory disease and extramedullary disease (EMD). Among 90 treated patients, the overall response rate (ORR) was 78.9%, with a complete response (CR) or better in 54.4%. Median duration of response was 13.8 months, and 61% of responders remained on therapy at data cutoff. Responses were consistent across high-risk subgroups, including prior BCMA CAR-T exposure and prior anti-FcRH5 bispecific therapy. The combination was generally well tolerated, although grade ≥3 infections were more frequent compared to monotherapy. Cytokine release syndrome and taste-related adverse events were manageable. This study represents the first evaluation of dual bispecific therapy in this setting and suggests potential for use as an off-the-shelf alternative to CAR-T therapies, particularly in patients with limited options or EMD.‍

Citation: https://www.jnj.com/media-center/press-releases/novel-combination-of-talvey-talquetamab-tgvs-and-tecvayli-teclistamab-cqyv-suggests-high-response-rates-and-durable-responses-in-triple-class-refractory-patients-with-relapsed-or-refractory-multiple-myeloma-including-those-with-extramedullary-disease

Implication: Dual bispecifics may emerge as an alternative to CAR-T in high-risk R/R MM subtypes.

‍